ENDO: Farxiga Proves Effective in T1D, But Is it Safe? (CME/CE)
(MedPage Today) -- Risk of ketoacidosis when dapagliflozin added to liraglutide and insulin (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 5, 2016 Category: Consumer Health News Source Type: news
Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016). (Source: World Pharma News)
Source: World Pharma News - April 4, 2016 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
Dual device-drug therapy improves uncontrolled diabetes and obesity
Combining a temporary one-year intestinal bypass device with the drug liraglutide helps patients lose weight and improve their diabetes control better than using either the device or the drug alone, new research reports. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 3, 2016 Category: Science Source Type: news
VIDEO: Liraglutide acts on GLP-1 receptors to lessen desire for high-fat foods
BOSTON – Two related studies of brain structure and the mechanism of the analog of glucagon-like peptide (GLP) hormone liraglutide indicate that the drug works to decrease reward-related activation... (Source: Family Practice News)
Source: Family Practice News - April 3, 2016 Category: Primary Care Source Type: news
Liraglutide may make high-fat foods less desirable to the brain's reward centers
A new study finds that the diabetes drug liraglutide leads to weight loss by acting on an area of the brain that controls attention and possibly making desirable foods less rewarding. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 2, 2016 Category: Science Source Type: news
Dual device-drug therapy improves uncontrolled diabetes and obesity
(The Endocrine Society) Combining a temporary one-year intestinal bypass device with the drug liraglutide helps patients lose weight and improve their diabetes control better than using either the device or the drug alone, new research from the United Kingdom reports. The one-year results of the two-year study will be presented in a poster Saturday, April 2, at ENDO 2016, the annual meeting of the Endocrine Society in Boston. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 2, 2016 Category: Global & Universal Source Type: news
Liraglutide may make high-fat foods less desirable to the brain's reward centers
(The Endocrine Society) A new study finds that the diabetes drug liraglutide leads to weight loss by acting on an area of the brain that controls attention and possibly making desirable foods less rewarding. Researchers will present their results Saturday at the Endocrine Society's 98th annual meeting in Boston. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 2, 2016 Category: Global & Universal Source Type: news
Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
Novo Nordisk has announced the top-line results from the LEADER trial, which investigated the cardiovascular safety of Victoza® (liraglutide) over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events. (Source: World Pharma News)
Source: World Pharma News - March 14, 2016 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
Top-Line Data Show CV Benefit for Liraglutide Top-Line Data Show CV Benefit for Liraglutide
Liraglutide is the third diabetes drug to show CV benefit and the first for the GLP-1 class. News Alerts (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 4, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
Top-Line Data Show CV Benefit for Liraglutide in Type 2 DiabetesTop-Line Data Show CV Benefit for Liraglutide in Type 2 Diabetes
Liraglutide is the third diabetes drug to show CV benefit and the first for the GLP-1 class. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 4, 2016 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
CardioBrief: Big Victoza Trial Confirms Cardiovascular Benefit
(MedPage Today) -- Drug cut CV deaths, heart attacks, strokes in LEADER, says manufacturer (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 4, 2016 Category: Cardiology Source Type: news
Morning Break: Big Win for Victoza; Cancer's Achilles Heel; Abortion Travel Agent
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 4, 2016 Category: American Health Source Type: news
Novo Nordisk says Victoza helps lower heart risks
COPENHAGEN (Reuters) - Novo Nordisk said on Friday the results from a trial showed that its Victoza diabetes drug significantly reduced the risks of major adverse cardiovascular events. (Source: Reuters: Health)
Source: Reuters: Health - March 4, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Degludec/Liraglutide Combo Bests Glargine in Type 2 DiabetesDegludec/Liraglutide Combo Bests Glargine in Type 2 Diabetes
Combination insulin/GLP-1 agonist injectable improves glycemic control and reduces weight with less hypoglycemia compared with glargine-based regimen. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 3, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Eli Lilly launches once-a-week diabetes drug in India
The once-a-week non-insulin injectable Trulicity is distinct in the duration of dosage compared to products like Novo Nordisk's Victoza or Sanofi's Lantus. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 3, 2016 Category: Pharmaceuticals Source Type: news
